28.22
07-May-25 16:45:00
15 minutes delayed
Stocks
-0.10
-0.35%
Today's range
28.08 - 28.63
ISIN
N/A
Source
NASDAQ
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
26 Jan 2021 16:01:00 By Nasdaq GlobeNewswire
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
17 Jan 2021 10:00:00 By Nasdaq GlobeNewswire
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
11 Jan 2021 07:00:01 By Nasdaq GlobeNewswire